KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Short-term Investments (2016 - 2025)

Nektar Therapeutics has reported Short-term Investments over the past 16 years, most recently at $230.6 million for Q4 2025.

  • Quarterly results put Short-term Investments at $230.6 million for Q4 2025, up 9.32% from a year ago — trailing twelve months through Dec 2025 was $230.6 million (up 9.32% YoY), and the annual figure for FY2025 was $230.6 million, up 9.32%.
  • Short-term Investments for Q4 2025 was $230.6 million at Nektar Therapeutics, up from $229.2 million in the prior quarter.
  • Over the last five years, Short-term Investments for NKTR hit a ceiling of $887.2 million in Q1 2021 and a floor of $132.9 million in Q2 2025.
  • Median Short-term Investments over the past 5 years was $333.2 million (2023), compared with a mean of $415.3 million.
  • Biggest five-year swings in Short-term Investments: tumbled 49.18% in 2022 and later increased 9.32% in 2025.
  • Nektar Therapeutics' Short-term Investments stood at $708.7 million in 2021, then crashed by 41.2% to $416.8 million in 2022, then plummeted by 35.61% to $268.3 million in 2023, then dropped by 21.38% to $211.0 million in 2024, then rose by 9.32% to $230.6 million in 2025.
  • The last three reported values for Short-term Investments were $230.6 million (Q4 2025), $229.2 million (Q3 2025), and $132.9 million (Q2 2025) per Business Quant data.